AllSci News
Innovent Biologics advances IBI354 into pivotal first-line HER2-positive breast cancer trial
China-based Innovent Biologics (HKEX: 01801) announced the dosing of the first participant in HeriCare-Breast01, a pivotal Phase III study evaluating...
Opus Genetics raises USD 25m in private placement
U.S.-based Opus Genetics (Nasdaq: IRD) announced a USD 25 million private placement financing through the sale of Series B Non-Voting Convertible Preferred...
Ovid Therapeutics raises USD 60m in private placement to expand epilepsy pipeline
Ovid Therapeutics Inc. (Nasdaq: OVID), a New York-based biopharmaceutical company developing small molecule therapies for neurological disorders, announced...
ARTHEx Biotech Secures FDA Fast Track Designation for ATX-01 in Myotonic Dystrophy Type 1
ARTHEx Biotech, a clinical-stage biotechnology company headquartered in Valencia, Spain, announced that the U.S. Food and Drug Administration (FDA) has...
Lilly's selpercatinib meets primary endpoint in adjuvant RET fusion-positive lung cancer trial
Eli Lilly announced positive topline results from the Phase III LIBRETTO-432 trial evaluating Retevmo (selpercatinib), a selective RET kinase inhibitor, as...
FDA accepts Cogent Biosciences' NDA for bezuclastinib in non-advanced systemic mastocytosis
Cogent Biosciences announced that the US FDA has accepted its New Drug Application for bezuclastinib in patients with non-advanced systemic mastocytosis...
Seaport Therapeutics Receives Up to $15M ARPA-H Award to Advance Lymphatic-Targeted Oral Prodrug
Boston-based Seaport Therapeutics, a clinical-stage company focused on neuropsychiatric medicines, has received a non-dilutive award of up to USD 15 million...
Altesa BioSciences Closes USD 75 Million Series B to Advance Rhinovirus Antiviral Therapy
Altesa BioSciences, a clinical-stage company headquartered in Atlanta focused on developing antiviral therapies for chronic lung disease, has closed an...
Response Pharmaceuticals' RDX-002 shows positive phase 2 results for post-GLP-1 obesity weight management
Virginia-based Response Pharmaceuticals announced 36-week Phase 2 data for RDX-002, a gut-restricted inhibitor of intestinal microsomal triglyceride...
Ovid Therapeutics raises USD 60m in private placement
Ovid Therapeutics Inc. (Nasdaq: OVID), a New York-based biopharmaceutical company developing small molecule therapies for brain disorders, announced a USD...
FDA approves Rocket Pharmaceuticals' gene therapy Kresladi for severe pediatric leukocyte adhesion deficiency-I
The US FDA has granted accelerated approval to KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy developed by...
Roche's giredestrant advances toward FDA review for ESR1-mutated breast cancer treatment
Roche announced that the US FDA has accepted a New Drug Application for giredestrant, an oral selective oestrogen receptor degrader (SERD), in combination...
IMUNON's IMNN-001 shows 14.7-month survival benefit in advanced ovarian cancer phase II trial
IMUNON, Inc., a clinical-stage biotechnology company based in Lawrenceville, N.J., reported final Phase II data from the OVATION 2 trial evaluating IMNN-001...
Pfizer's talazoparib plus enzalutamide meets Phase III endpoint in metastatic castration-sensitive prostate cancer
Pfizer (NYSE: PFE) announced positive topline results from the Phase III TALAPRO-3 trial evaluating Talzenna (talazoparib) plus Xtandi (enzalutamide) in...
Xenon Pharmaceuticals raises USD 747.5m in upsized public offering
Canada-based Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company with offices in Vancouver and Boston, announced the...
The AllSci Brief
Systematic R&D and deal news. Daily.